CCL5 Stem Cell Mobilization Composition for Faster Engraftment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for collecting and transplanting hematopoietic stem cells are inefficient and time-consuming, with low engraftment rates, limiting the effectiveness of bone marrow transplantation treatments for blood disorders.
Innovation Solution
A composition comprising C-C motif chemokine ligand 5 (CCL5) protein, growth-related oncogene beta (GROβ), and AMD3100, a CXCR4 antagonist, is used to enhance the migration and engraftment of bone marrow-derived stem cells, facilitating their collection and improving treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If G-CSF is used to collect hematopoietic stem cells from peripheral blood, then stem cell collection is enabled, but the process requires daily injections for 4 to 5 days and extensive blood processing, resulting in time consumption and operational complexity
Solution Approach 1:
The patent applies preliminary action by administering CCL5, GROβ, and AMD3100 to the donor before stem cell collection to pre-mobilize hematopoietic stem cells into peripheral blood. This preliminary treatment enables efficient stem cell collection in a single procedure rather than requiring multiple days of G-CSF injections and extensive processing, thus resolving the contradiction between collection efficiency and time consumption
Solution Approach 2:
The patent uses CCL5 as an intermediary chemokine that mediates stem cell mobilization from bone marrow to peripheral blood. Combined with GROβ and AMD3100, CCL5 acts as a key mediator that facilitates stem cell release and migration, enabling efficient collection without the time-consuming G-CSF protocol. This intermediary mechanism resolves the contradiction by providing a more direct and faster pathway for stem cell retrieval
2Reliability
If conventional stem cell transplantation methods are used, then treatment can proceed, but the engraftment rate is low and bone marrow function recovery takes considerable time
Solution Approach 1:
The patent applies preliminary action by treating the donor with CCL5, GROβ, and AMD3100 before stem cell collection to enhance the quality and mobilization status of stem cells. This preliminary treatment ensures that the collected stem cells have improved engraftment capability, leading to higher engraftment rates and faster bone marrow recovery in recipients, thus resolving the contradiction between engraftment reliability and recovery time
Solution Approach 2:
The patent changes the biochemical parameters of stem cells through CCL5, GROβ, and AMD3100 treatment, altering their migration and engraftment properties. This parameter change enhances the functional characteristics of stem cells, improving engraftment rates and accelerating bone marrow recovery, thereby resolving the contradiction between engraftment reliability and time for function recovery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly increases the migration of hematopoietic stem cells to peripheral blood and enhances engraftment rates, providing a more effective treatment for bone marrow diseases requiring transplantation.
Implementation Method 1
C-C motif chemokine ligand 5 (CCL5), a niche enhancing factor, not only increases migration of bone marrow-derived hematopoietic stem cells into peripheral blood
Implementation Method 2
AMD3100, a CXCR4 antagonist
Data Source
AI summary
The present disclosure relates to a composition for promoting the activation of bone marrow-derived stem cells, including C-C motif chemokine ligand 5 (CCL5), wherein, when CCL5 is administered together with growth-related oncogene beta (GROβ) and AMD3100, it not only increases the migration of hematopoietic stem cells from bone marrow to peripheral blood, but also enhances the engraftment efficiency when the hematopoietic stem cells are transplanted into recipients.